Apellis Pharmaceuticals, Inc. (APLS) Misses Q3 EPS by 17c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q3 EPS of ($0.46), $0.17 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $196.83 million versus the consensus estimate of $200.09 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
• North Korea dismisses US military drill cuts, denies Trump talks
• Moderna short sellers face $4.8 billion loss amid record stock jump